Publikationen


Dynamic Contrast-Enhanced MR Imaging Evaluation of Perfusional Changes and Ablation Zone Size after Combination Embolization and Ablation Therapy

19.12.2022

Jason Chiang, MD, PhD, Hiro Sparks, MD, Johann S. Rink, MD, M. Franca Meloni, MD, Frank Hao, MD, Kyung H. Sung, PhD, and Edward W. Lee, MD, PhD Journal of Vascular and Interventional Radiology https://doi.org/10.1016/j.jvir.2022.10.041 Available online 8 November 2022 Received 4 June 2022, Revised 29 September 2022, Accepted 28 October 2022, Available online 8

... weiter lesen

Synthesis of a new bifunctional cross-bridged chelating agent, peptide conjugation, and comparison of 68Ga-labeling and complex stability characteristics with established chelators

19.10.2022

Damerow H, Wängler B, Schirrmacher R, Fricker G, Wängler C* (2023) Synthesis of a new bifunctional cross-bridged chelating agent, peptide conjugation, and comparison of 68Ga-labeling and complex stability characteristics with established chelators. ChemMedChem 18(1), e202200495. DOI: 10.1002/cmdc.202200495. Graphical Abstract The new backbone-modified bifunctional cross-bridged chelating agent CB-DO2A-GA was developed, introduced into the peptide Tyr3-octreotate and

... weiter lesen

Toward Optimized 89Zr-Immuno-PET: Side-by-Side Comparison of [89Zr]Zr-DFO-, [89Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [89Zr]Zr-DFO*-Cetuximab for Tumor Imaging – Which Chelator is the Most Suitable?

04.10.2022

Damerow H, Cheng X, von Kiedrowski V, Schirrmacher R, Wängler B, Fricker G, Wängler C* (2022) Toward Optimized 89Zr-Immuno-PET: Side-by-Side Comparison of [89Zr]Zr-DFO-, [89Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [89Zr]Zr-DFO*-Cetuximab for Tumor Imaging – Which Chelator is the Most Suitable? Pharmaceutics 14(10), 2114. DOI: 10.3390/pharmaceutics14102114. Published: 4 October 2022 https://doi.org/10.3390/pharmaceutics14102114 Abstract 89Zr represents a highly favorable positron emitter for

... weiter lesen

Favorable SSTR subtype selectivity of SiTATE: new momentum for clinical [18F]SiTATE PET

05.09.2022

Wängler C, Beyer L, Bartenstein P, Wängler B, Schirrmacher R, Lindner S (2022) Favorable SSTR Subtype Selectivity of SiTATE: New momentum for clinical [18F]SiTATE PET. EJNMMI Radiopharmacy and Chemistry, 7(1), 22. DOI: 10.1186/s41181-022-00176-x. Published 05 September 2022 DOI: https://doi.org/10.1186/s41181-022-00176-x

... weiter lesen

Synthetic Arterial Spin Labeling MRI of the Kidneys for Evaluation of Data Processing Pipeline

31.07.2022

I. Brumer, D. Bauer, L. Schad and F. Zöllner. Synthetic Arterial Spin Labeling MRI of the Kidneys for Evaluation of Data Processing Pipeline. Diagnotsics, 2022, 12 (8), p.1854 . Published: 31 July 2022 https://doi.org/10.3390/diagnostics12081854 Abstract Accurate quantification of perfusion is crucial for diagnosis and monitoring of kidney function. Arterial spin labeling (ASL), a completely non-invasive magnetic

... weiter lesen

Towards the development of GE11-based radioligands for imaging of EGFR-positive tumors

28.07.2022

Judmann B, Braun D, Schirrmacher R, Wängler B, Fricker G, Wängler C* (2022) Towards the development of GE11-based radioligands for imaging of EGFR-positive tumors. ACS Omega, 7(31), 27690–27702. DOI: 10.1021/acsomega.2c03407. Publication Date: July 28, 2022 https://doi.org/10.1021/acsomega.2c03407 Abstract The epidermal growth factor receptor (EGFR) is closely associated with tumor development and progression and thus an important

... weiter lesen

Feature-based CBCT self-calibration for arbitrary trajectories

20.05.2022

C. Tönnes, T. Russ, L. Schad and F. Zöllner. Feature-based CBCT Self-Calibration for Arbitrary Trajectories.Int J CARS, 2022, 17 (11), pp. 2151-2159 Published 20 May 2022 https://doi.org/10.1007/s11548-022-02645-9 Abstract Purpose Development of an algorithm to self-calibrate arbitrary CBCT trajectories which can be used to reduce metal artifacts. By using feature detection and matching we want to reduce

... weiter lesen

Development of an abdominal phantom for the validation of an oligometastatic disease diagnosis workflow

16.05.2022

Dominik F. Bauer, Julian Rosenkranz, Alena-Kathrin Golla, Christian Tönnes, Ingo Hermann, Tom Russ, Gordian Kabelitz, Andreas J. Rothfuss, Lothar R. Schad, Jan L. Stallkamp, Frank G. Zöllner Med Phys.2022;1–10.First published: 05 May 2022 https://doi.org/10.1002/mp.15701 Abstract Purpose The liver is a common site for metastatic disease, which is a challenging and life-threatening condition with a grim

... weiter lesen

Deep Learning-Based Total Kidney Volume Segmentation in Autosomal Dominant Polycystic Kidney Disease Using Attention, Cosine Loss, and Sharpness Aware Minimization

07.05.2022

A. Raj, F. Tollens, L. Hansen, A. Golla, L. Schad, D. Nörenberg and F. Zöllner. Deep Learning-Based Total Kidney Volume Segmentation in Autosomal Dominant Polycystic Kidney Disease Using Attention, Cosine Loss, and Sharpness Aware Minimization. Diagnostics, 2022, 12 (5), p.1159  Published: 7 May 2022 https://doi.org/10.3390/diagnostics12051159 Abstract Early detection of the autosomal dominant polycystic kidney disease (ADPKD)

... weiter lesen

Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms: A Markov Model-Based Cost-Effectiveness Analysis

25.04.2022

Rink JS, Froelich MF, McWilliams JP, Gratzke C, Huber T, Gresser E, Schoenberg SO, Diehl SJ, Nörenberg D. Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms: A Markov Model-Based Cost-Effectiveness Analysis. J Am Coll Radiol. 2022 Jun;19(6):733-743. doi: 10.1016/j.jacr.2022.02.040. Epub 2022 Apr 25. PMID: 35476943. DOI: 10.1016/j.jacr.2022.02.040 Abstract Purpose: The aim of this

... weiter lesen